Compare Dollar Tree, Inc. (DLTR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Dollar Tree, Inc. trades at $118.58 (market cap $22.26B), while Recursion Pharmaceuticals Inc trades at $4.23 (market cap $2.14B). The key difference: Dollar Tree, Inc. is far larger — about 10.4× Recursion Pharmaceuticals Inc's market cap, and Dollar Tree, Inc. is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dollar Tree, Inc. for 58 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| DLTR | RXRX | |
|---|---|---|
Market Cap | $22.26B | $2.14B |
Volume | 2,317,428 | 30,789,535 |
Sector | Consumer Staples | Health |
52-Week High | $141.21 | $6.79 |
52-Week Low | $86.80 | $2.84 |
Typical Hold Time | 58 Days | 23 Days |
Enterprise Value | $28.87B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $117.42, up 0.96% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with a 45.87% ROE and trades at a modest P/E of 14.54. Recent news highlights strategic initiatives and store expansions supporting growth, though margin risks from tariffs and reinvestment remain a focus.
The outlook is positive with a consensus price target of $139.33, implying 18.7% upside, but investors face risks from volatile margins, high debt levels, and competitive pressures. Earnings improvement and institutional buying provide support, yet the stock's recent decline of 17.9% over the past month underscores near-term challenges.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
